Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Hamblin

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Neurology|October 15, 2017
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional seriesJeffrey M Gelfand, Michael J Bradshaw, Barney J Stern, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Neurology|October 15, 2017
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional seriesJeffrey M Gelfand, Michael J Bradshaw, Barney J Stern, et al.
Pageof 2